Adapalene (Differin)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Acne vulgaris | ≥12 years | Monotherapy or combination with antimicrobials/benzoyl peroxide | FDA Approved |
Adapalene is FDA-approved for the topical management of acne vulgaris in patients aged 12 years and older. It is available in multiple formulations including gel (0.1% and 0.3%), cream (0.1%), and lotion (0.1%). The 0.1% gel was reclassified for over-the-counter availability in 2016, making it the first retinoid approved for OTC acne treatment in the United States. Current guidelines from the American Academy of Dermatology and the Global Alliance to Improve Outcomes in Acne position topical retinoids, including adapalene, as first-line agents for both comedonal and mild-to-moderate inflammatory acne.
Photoaging and fine wrinkles — Evidence quality: Moderate. Adapalene 0.3% gel has demonstrated improvement in fine wrinkles and skin texture in clinical studies, though it is not as extensively studied as tretinoin for this indication.
Post-inflammatory hyperpigmentation — Evidence quality: Moderate. Accelerates epidermal turnover and may enhance resolution of pigmentary changes following acne or other inflammatory dermatoses.
Molluscum contagiosum — Evidence quality: Low. Case series suggest adapalene may promote resolution by modulating keratinization around molluscum bodies.
Verrucae (warts) — Evidence quality: Low. Limited case reports describe benefit in flat warts through effects on keratinocyte differentiation.
Keratosis pilaris — Evidence quality: Low. Used off-label to reduce follicular plugging, though controlled trial data are limited.
Actinic keratoses — Evidence quality: Low. Some evidence in mild actinic keratoses, but not a standard of care.
Dosing
Adult and Adolescent Dosing (≥12 years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild comedonal acne — first-line monotherapy | 0.1% gel, once daily (evening) | 0.1% gel, once daily | 0.1% gel, once daily | Apply thin film to entire affected area after gentle cleansing Available OTC; preferred for initial retinoid use |
| Moderate acne — combination with benzoyl peroxide | 0.1%/BPO 2.5% fixed-dose gel, once daily (evening) | 0.1%/BPO 2.5%, once daily | 0.1%/BPO 2.5%, once daily | Pea-sized amount per facial zone (forehead, each cheek, chin) Fixed-dose combination is approved for ≥9 years |
| Moderate-to-severe acne — prescription-strength monotherapy | 0.3% gel, once daily (evening) | 0.3% gel, once daily | 0.3% gel, once daily | Prescription only; re-evaluate if no improvement at 12 weeks Greater efficacy vs 0.1% gel but higher irritation rates |
| Acne — sensitive or dry skin | 0.1% cream, once daily (evening) | 0.1% cream, once daily | 0.1% cream, once daily | Cream vehicle is less drying than gel Prescription formulation; consider for eczema-prone skin |
| Acne — large body surface area (face + trunk) | 0.1% lotion, once daily (evening) | 0.1% lotion, once daily | 0.1% lotion, once daily | Lotion vehicle spreads easily over larger areas Approved for ≥12 years; lower systemic absorption than 0.3% gel |
| Acne maintenance — after initial clearance | 0.1% gel or cream, once daily | 0.1% gel or cream, once daily | 0.1% gel or cream, once daily | Continue long-term to prevent relapse Retinoid maintenance is guideline-recommended |
For patients new to topical retinoids, consider short-contact therapy (applying for 30–60 minutes before washing off) for the first 1–2 weeks, then advancing to overnight use. Alternatively, begin with every-other-night application and increase to nightly as tolerated. A non-comedogenic moisturizer applied 5–10 minutes after adapalene markedly reduces initial irritation. Visible improvement typically begins at 4–8 weeks, with full benefit by 12 weeks. An initial “purging” phase (temporary worsening of acne) during weeks 2–4 is expected and should not prompt premature discontinuation.
Pharmacology
Mechanism of Action
Adapalene is a synthetic naphthoic acid derivative that acts as a selective agonist at nuclear retinoic acid receptors (RAR), with preferential binding to RAR-beta and RAR-gamma subtypes. Unlike first-generation retinoids such as tretinoin, adapalene does not bind to cytosolic retinoid-binding proteins or retinoid X receptors (RXR), which likely contributes to its improved tolerability and reduced off-target effects. Once bound to RARs, the adapalene-receptor complex dimerizes with RXR and binds to specific DNA response elements, modulating gene transcription involved in keratinocyte proliferation and differentiation.
The downstream clinical effects are threefold. First, adapalene normalizes follicular epithelial differentiation, reducing the formation of microcomedones — the precursor lesion of all acne. Second, it accelerates epidermal turnover and promotes exfoliation, facilitating clearance of existing comedones. Third, adapalene exerts direct anti-inflammatory activity by inhibiting lipoxygenase pathways and the oxidative metabolism of arachidonic acid, suppressing the inflammatory response triggered by Cutibacterium acnes. This combination of comedolytic, keratolytic, and anti-inflammatory actions makes adapalene effective against both non-inflammatory and inflammatory acne lesions.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Minimal systemic absorption (<5% of applied dose); Cmax ~0.553 ng/mL with 0.3% gel on face/chest/back; undetectable (<0.25 ng/mL) with 0.1% gel | Very low systemic exposure makes drug interactions and systemic toxicity unlikely at recommended doses |
| Distribution | Highly lipophilic; concentrates in epidermis and dermis; >99% bound in blood (plasma proteins); 26% bound to erythrocytes | Local skin concentration is therapeutically relevant; penetrates hair follicles within 5 minutes of application |
| Metabolism | ~25% metabolized; major products are glucuronide conjugates; accumulates in liver; no CYP-mediated metabolism identified | Absence of CYP involvement means minimal risk of pharmacokinetic drug interactions |
| Elimination | t½ = 7–51 h (mean 17.2 h); primarily biliary excretion; ~75% excreted unchanged; cleared from plasma within 72 h of last application | Rapid plasma clearance after treatment cessation; no dose adjustment needed for renal or hepatic impairment |
Side Effects
The majority of adverse effects with adapalene are local cutaneous reactions that are dose-dependent, occur early in treatment, and diminish with continued use. Rates below are drawn from the FDA-approved prescribing information for the 0.3% gel pivotal 12-week trial (N=258 for local reactions; N=553 for the 1-year open-label extension) and the 0.1% gel labelling.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Erythema | 10–40% | Most prominent during first 2–4 weeks; usually mild-to-moderate; improves with continued use |
| Scaling / Dryness | 10–40% | Managed with non-comedogenic moisturizer; more frequent with gel vs cream vehicle |
| Burning / Stinging on application | ~20% | Transient; occurs immediately after application; self-limiting within minutes |
| Dry skin (0.3% gel) | 14.0% | Higher with 0.3% gel than 0.1% formulations; correlates with greater treatment efficacy |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Skin discomfort (0.3% gel) | 5.8% | General discomfort beyond stinging; frequency-reduce or add moisturizer |
| Sunburn | 1.2–2% | Retinoid-induced photosensitivity; reinforce sun protection counselling |
| Pruritus (0.3% gel) | 1.9% | Usually mild; resolve with continued use or frequency reduction |
| Desquamation (0.3% gel) | 1.6% | Visible peeling; part of normal retinoid response; self-limited |
| Skin irritation / Burning/stinging (0.1% gel) | ~1% | Lower incidence than 0.3% gel; most common during first month |
| Acne flare (purging) | <1% | Temporary worsening during weeks 2–4 as microcomedones surface; not a reason to discontinue |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Anaphylaxis / Anaphylactoid reaction | Very rare (post-marketing) | Any time during treatment | Immediate discontinuation; emergency medical treatment; permanent discontinuation of adapalene |
| Angioedema (face, eyelid, lip swelling) | Very rare (post-marketing) | Any time during treatment | Discontinue adapalene; treat with antihistamines or corticosteroids as indicated; refer to allergy specialist if recurrent |
| Severe contact dermatitis / Hypersensitivity | Rare (<1%) | First 1–4 weeks | Discontinue use; topical corticosteroid for symptom relief; do not rechallenge if true hypersensitivity |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Severe local irritation (erythema, scaling, burning) | <5% (estimated) | Most common reason; usually avoidable with gradual titration and moisturizer use |
| Contact dermatitis / Hypersensitivity | <1% | True allergy; requires permanent discontinuation |
Local cutaneous irritation is expected but manageable. Strategies include: (1) gentle, non-medicated cleanser before application; (2) waiting until skin is fully dry (~10 minutes) before applying adapalene; (3) applying a non-comedogenic moisturizer before or after adapalene (the “sandwich” or “buffering” technique); (4) starting with every-other-night application and advancing to nightly over 2–4 weeks; (5) avoiding concomitant use of astringents, products with high alcohol content, or abrasive cleansers.
Drug Interactions
Adapalene has minimal systemic absorption and is not metabolized through cytochrome P450 enzymes, making systemic pharmacokinetic drug interactions extremely unlikely. The clinically relevant interactions are topical (irritant or photosensitizing combinations) and pharmacodynamic (additive retinoid effects).
Monitoring
Adapalene requires no routine laboratory monitoring due to its minimal systemic absorption. Monitoring is clinical and focused on local skin tolerance and treatment response.
-
Local Skin Tolerance
Weeks 2, 4, 8, 12
Routine Assess erythema, scaling, dryness, and burning/stinging severity. Most local reactions peak during weeks 1–4 and should improve with continued use. Reduce frequency or add moisturizer if moderate-to-severe irritation persists beyond 4 weeks. -
Treatment Response
Week 12
Routine Evaluate reduction in inflammatory and non-inflammatory lesion counts. If no meaningful improvement by 12 weeks, consider step-up to 0.3% gel, addition of a topical antimicrobial, or alternative retinoid. The FDA label recommends re-evaluation if no benefit at 12 weeks. -
Pregnancy Status
Before initiation
Routine Confirm the patient is not pregnant and is using effective contraception if of childbearing potential, particularly for prescription-strength formulations. While systemic absorption is minimal, retinoids carry a class-wide teratogenic concern. -
Signs of Allergy
Any visit
Trigger-Based Watch for angioedema, eyelid or lip swelling, urticaria, or pruritus beyond expected retinoid irritation. These post-marketing reactions require immediate discontinuation and allergy work-up. -
Photoprotection Adherence
Every visit
Routine Confirm patient is using broad-spectrum sunscreen (SPF ≥30) and protective clothing during treatment. Adapalene increases photosensitivity, and sunburn has been reported in 1–2% of patients in clinical trials. -
Signs of Hyperandrogenism
At initial presentation
Trigger-Based Per AAD guidance, if acne is accompanied by signs of androgen excess (hirsutism, alopecia, menstrual irregularity), obtain laboratory evaluation (DHEA-S, total/free testosterone, +/- 17-hydroxyprogesterone) to exclude an endocrine cause before initiating topical-only therapy.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to adapalene or any excipient in the formulation (carbomer, edetate disodium, methylparaben, poloxamer, propylene glycol, sodium hydroxide).
Relative Contraindications (Specialist Input Recommended)
- Pregnancy — Oral adapalene is teratogenic in animal studies at doses 40–81 times the maximum recommended human dose. Although topical systemic absorption is minimal (safety margin ≥70-fold), there are insufficient human data to establish safety. Avoid use in pregnant patients; if a patient becomes pregnant during treatment, discontinue immediately and counsel accordingly.
- Breastfeeding — Unknown whether adapalene is excreted in human milk after topical application (present in rat milk with oral dosing). If used, apply to the smallest area for the shortest duration possible and avoid application near the breast to minimize infant exposure.
Use with Caution
- Active sunburn or sunburned skin — Do not apply to sunburned skin; wait until fully recovered before initiating treatment.
- Eczematous or broken skin — Adapalene should not be applied to cuts, abrasions, or areas of eczema due to increased risk of local irritation and systemic absorption through compromised barrier.
- Patients with high sun exposure or inherent photosensitivity — Adapalene increases susceptibility to UV damage; emphasize rigorous photoprotection.
- Concurrent waxing — Wax epilation should be avoided on treated skin due to the risk of skin erosion from retinoid-thinned stratum corneum.
- Pediatric patients <12 years — Safety and efficacy have not been established in children younger than 12 years for single-agent adapalene (the adapalene/BPO fixed combination is approved for ≥9 years).
- Geriatric patients (≥65 years) — No clinical trial data in patients aged 65 and older; safety and effectiveness have not been established in this population.
All retinoids carry a class-wide concern for teratogenicity. While topical adapalene has dramatically lower systemic exposure compared to oral retinoids such as isotretinoin, oral administration to pregnant rats and rabbits at high doses (40–81 times the MRHD) produced skeletal and visceral malformations including cleft palate, encephalocele, and kidney abnormalities. Women of childbearing potential should be counselled about contraception before initiating prescription-strength adapalene. Adapalene does not have an FDA boxed warning, and no formal pregnancy prevention program (like iPLEDGE for isotretinoin) is required for topical adapalene.
Patient Counselling
Purpose of Therapy
Adapalene is a retinoid (vitamin A derivative) applied to the skin to treat acne. It works by normalizing how skin cells grow and shed inside pores, which prevents new acne lesions from forming. It also reduces the redness and inflammation associated with acne. Adapalene treats existing acne and prevents future breakouts, but it takes time — most patients begin to see improvement at 4–8 weeks, with the full benefit appearing by 12 weeks of consistent use.
How to Take
Apply a thin layer of adapalene to the entire affected area (not just individual spots) once daily in the evening, after washing gently with a mild, non-medicated cleanser and allowing the skin to dry completely. Use a pea-sized amount for the entire face. Avoid contact with eyes, lips, the corners of the nose, and mucous membranes. If using a moisturizer, it can be applied before or after adapalene depending on your skin’s tolerance.
Sources
- Differin (adapalene) Gel, 0.3% — Full Prescribing Information. Galderma Laboratories, L.P. Revised 2023. FDA Label Primary source for 0.3% gel dosing, adverse reaction incidence rates, pharmacokinetic data, and pregnancy/lactation recommendations.
- Differin (adapalene) Gel, 0.1% — Full Prescribing Information. Galderma Laboratories, L.P. FDA Label Source for 0.1% OTC gel labelling, including the 10–40% local cutaneous irritation rates from earlier controlled trials.
- Differin (adapalene) Gel, 0.1% (Original NDA 20-380) — Full Prescribing Information. FDA Label (2007) Original 0.1% gel PI with historical adverse effect data and pharmacokinetic absorption studies.
- Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996;34(3):482-485. PubMed: 8609263 Pivotal head-to-head trial establishing equivalent efficacy of adapalene to tretinoin with superior tolerability.
- Millikan LE. Pivotal clinical trials of adapalene in the treatment of acne. J Eur Acad Dermatol Venereol. 2001;15 Suppl 3:19-22. PubMed: 11843229 Review of three large pivotal trials confirming adapalene’s efficacy profile and faster onset of action vs tretinoin.
- Brogden RN, Goa KL. Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs. 1997;53(3):511-519. PubMed: 9074847 Comprehensive pharmacological review covering ADME, receptor binding, and comparative clinical trial data.
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. DOI: 10.1016/j.jaad.2015.12.037 AAD evidence-based guideline positioning topical retinoids as first-line therapy for acne and recommending retinoid maintenance.
- Dréno B, Bettoli V, Araviiskaia E, et al. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018;32(5):812-819. DOI: 10.1111/jdv.14820 European consensus on acne management factors including retinoid use in the context of environmental and lifestyle exposures.
- Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997;36(6 Pt 2):S96-S103. PubMed: 9204085 Foundational paper describing adapalene’s RAR-beta/gamma selectivity, chemical stability, and anti-inflammatory pharmacology.
- Bernard BA. Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol. 1993;6 Suppl 1:61-69. PubMed: 8142113 Early characterization of adapalene’s retinoid receptor binding profile and differentiation from tretinoin at the molecular level.
- Tolaymat L, Dearborn H, Zito PM. Adapalene. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. NCBI Bookshelf: NBK482509 Comprehensive overview of adapalene pharmacokinetics (absorption, distribution, half-life), off-label uses, and pregnancy considerations.
- FDA NDA 020380 Rx-to-OTC Switch Review — Adapalene Gel 0.1%. 2016. FDA Review FDA review supporting OTC reclassification; includes safety margin calculations for topical use in pregnancy and consumer use data.
- Differin Product Monograph (Canadian). Galderma Canada Inc. Revised December 2018. Health Canada PM Canadian product monograph providing additional protein binding data (>99% in blood, 26% erythrocyte-bound) and PK steady-state assessment.